ArticleFrontiers in medicine2026
Association of comorbidity burden with initial treatment allocation in older women with gynecologic cancer: a retrospective cohort study.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Comorbidity is a key determinant of treatment decisions in older cancer patients; however, its role in shaping initial treatment allocation among older women with gynecologic malignancies remains insufficiently characterized. We aimed to evaluate the association between comorbidity burden and treatment selection and to develop a clinically interpretable predictive model. Methods: We retrospectively analyzed 972 women aged ≥65 years with newly diagnosed cervical, ovarian, or endometrial cancer treated at a tertiary hospital in Southwest China between 2019 and 2024. Disease-specific guideline-concordant standard treatment was defined as curative-intent initial treatment appropriate for tumor type and FIGO stage, including surgery, platinum-based chemotherapy, concurrent chemoradiotherapy, brachytherapy, or combined-modality treatment when indicated. Multivariable logistic regression was used to identify independent predictors of disease-specific guideline-concordant standard treatment, and a predictive model was developed and internally validated with assessments of discrimination, calibration, and clinical utility. Results: Of the 972 patients, 63.7% received disease-specific guideline-concordant standard treatment. Higher comorbidity burden [Charlson Comorbidity Index (CCI) ≥ 4], ECOG performance status ≥2, age ≥75 years, and pulmonary disease were independently associated with lower odds of receiving disease-specific guideline-concordant standard treatment (all Conclusion: In this pooled real-world observational cohort of older women with cervical, ovarian, or endometrial cancer, comorbidity burden was independently associated with receipt of disease-specific guideline-concordant standard treatment. The internally validated host-factor-oriented model may support individualized treatment discussions as an adjunct to multidisciplinary assessment, but it should not be interpreted as a tumor-specific treatment algorithm or as a replacement for disease-specific guideline-based decision-making. Further external validation and tumor-specific prospective studies are needed before broader clinical implementation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.